» Articles » PMID: 32948088

Gene Expression Signature of Acquired Chemoresistance in Neuroblastoma Cells

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Sep 19
PMID 32948088
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Drug resistance of childhood cancer neuroblastoma is a serious clinical problem. Patients with relapsed disease have a poor prognosis despite intense treatment. In the present study, we aimed to identify chemoresistance gene expression signatures in vincristine resistant neuroblastoma cells. We found that vincristine-resistant neuroblastoma cells formed larger clones and survived under reduced serum conditions as compared with non-resistant parental cells. To identify the possible mechanisms underlying vincristine resistance in neuroblastoma cells, we investigated the expression profiles of genes known to be involved in cancer drug resistance. This specific gene expression patterns could predict the behavior of a tumor in response to chemotherapy and for predicting the prognosis of high-risk neuroblastoma patients. Our signature could help chemoresistant neuroblastoma patients in avoiding useless and harmful chemotherapy cycles.

Citing Articles

SAP30, an oncogenic driver of progression, poor survival, and drug resistance in neuroblastoma.

Prathipati P, Pathania A, Chaturvedi N, Gupta S, Byrareddy S, Coulter D Mol Ther Nucleic Acids. 2024; 35(2):101543.

PMID: 38817681 PMC: 11137595. DOI: 10.1016/j.omtn.2022.03.014.


Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma.

Italia M, Wertheim K, Taschner-Mandl S, Walker D, Dercole F Cancers (Basel). 2023; 15(7).

PMID: 37046647 PMC: 10093626. DOI: 10.3390/cancers15071986.


Cathepsin L promotes chemresistance to neuroblastoma by modulating serglycin.

Du X, Ding L, Huang S, Li F, Yan Y, Tang R Front Pharmacol. 2022; 13:920022.

PMID: 36133820 PMC: 9484481. DOI: 10.3389/fphar.2022.920022.


Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma.

Muller M, Rosch L, Najafi S, Gatzweiler C, Ridinger J, Gerloff X Cancers (Basel). 2021; 13(17).

PMID: 34503286 PMC: 8431508. DOI: 10.3390/cancers13174476.

References
1.
Alentorn A, Dehais C, Ducray F, Carpentier C, Mokhtari K, Figarella-Branger D . Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. Neurology. 2015; 85(15):1325-31. PMC: 4617162. DOI: 10.1212/WNL.0000000000002014. View

2.
Pearson A, Pinkerton C, Lewis I, Imeson J, Ellershaw C, Machin D . High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008; 9(3):247-56. DOI: 10.1016/S1470-2045(08)70069-X. View

3.
Kotchetkov R, Cinatl J, Blaheta R, Vogel J, Karaskova J, Squire J . Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer. 2003; 104(1):36-43. DOI: 10.1002/ijc.10917. View

4.
Kavallaris M . Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010; 10(3):194-204. DOI: 10.1038/nrc2803. View

5.
Jordan M . Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents. 2003; 2(1):1-17. DOI: 10.2174/1568011023354290. View